BackInter Pharma Public Company Limited Overview

Inter Pharma Public Company Limited Common Stock

Track Inter Pharma Public Company Limited's common stock ($300M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$302.67M
↑ 0.00% YoYΔ $0.00 vs prior year quarter

Peer trimmed avg / median

Loading

Inter Pharma Public Company Limited Common Stock History

Loading

Inter Pharma Public Company Limited vs. peers: Common Stock Comparison

Loading

Inter Pharma Public Company Limited Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Inter Pharma Public Company Limited (IP.BK) FAQ

Inter Pharma Public Company Limited's common stock stands at $300M as of June 2026. That compares with $300M in the prior-year period — up 0.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Inter Pharma Public Company Limited reported $300M in common stock versus $300M a year earlier — essentially flat versus a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $300M in the prior-year period — up 0.0% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Inter Pharma Public Company Limited's common stock evolved across reporting periods, while the comparison chart places IP.BK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. Inter Pharma Public Company Limited's reading of $300M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.